Sclerostin antibody promotes alveolar bone regeneration after tooth extraction

Erdal Ergünol1, Rabia Şemsi2, Duygu Dayanır3

  • 1Innovation, Education, Consultation and Organization Company, Alter Group, Istanbul, Türkiye.

PubMed

Insights

Sclerostin antibody (Scl-ab) significantly enhanced bone formation and increased bone volume in rabbit tooth extraction sockets. Localized inhibition of sclerostin promotes early bone regeneration and trabecular thickness.

Area of Science:

  • Bone biology and regenerative medicine
  • Wnt signaling pathway modulation
  • Osteoporosis research

Background:

  • Sclerostin inhibits bone formation by blocking Wnt signaling via LRP5/6 receptors.
  • Elevated sclerostin levels are linked to osteoporosis and increased osteoclast activity.
  • Targeting sclerostin offers a potential strategy for bone regeneration.

Purpose of the Study:

  • To evaluate the efficacy of sclerostin antibody (Scl-ab) in promoting bone formation within graft materials in tooth extraction sockets.
  • To analyze the effects of localized sclerostin inhibition on bone regeneration and tissue characteristics.

Main Methods:

  • New Zealand male rabbits were used, randomized into five groups (control, graft, and three Scl-ab dose groups).
  • Scl-ab was administered with graft material into extraction sockets, with assessments at 2 and 4 weeks.
  • Cone-beam computed tomography and histological analysis were employed to measure bone parameters.

Main Results:

  • Scl-ab treatment significantly increased the mean bone volume/tissue volume (BV/TV) ratio in extraction sockets.
  • A dose-dependent increase in bone volume was observed, with the highest dose showing the most significant enhancement.
  • Scl-ab administration significantly improved trabecular thickness of the alveolar bone compared to control and graft groups.

Conclusions:

  • Localized administration of sclerostin antibody effectively promotes early bone formation in tooth extraction sockets.
  • Scl-ab demonstrates therapeutic potential for enhancing bone regeneration by targeting sclerostin in the bone microenvironment.
  • This approach holds promise for treating conditions involving bone loss and facilitating socket healing.